SCHEMBL666503

SCHEMBL666503

Cn1cnc2c(Cl)nccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 1/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
TSHR P16473 1/20 0.53
EGLN1 Q9GZT9 1/20 0.48
RXFP1 Q9HBX9 1/20 0.42
DPP4 P27487 1/20 0.37
CDK1 P06493 1/20 0.37
YTHDC1 Q96MU7 1/20 0.35
RPS6KA5 O75582 1/20 0.35
RECQL P46063 1/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
AVPR1A P37288 1/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
ADORA2A P29274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30461799 1.00 KDM4E (0.53) KDM4EALDH1A1GLAGAATSHR
SCHEMBL15730603 0.78 ALDH1A1 (0.54) KDM4EALDH1A1GLAGAATSHR
SCHEMBL17873913 0.76 ALDH1A1 (0.53) KDM4EALDH1A1GLAGAATSHR
SCHEMBL6877790 0.76 KDM4E (0.53) KDM4EALDH1A1GLAGAATSHR
SCHEMBL4790823 0.76 RXFP1 (0.35) KDM4EALDH1A1GLAGAATSHR
SCHEMBL3449511 0.76 RPS6KA5 (0.41) KDM4EALDH1A1EGLN1RXFP1CDK1
SCHEMBL15723772 0.76 SMN1; SMN2 (0.41) ALDH1A1TSHRRXFP1CDK1MEN1
SCHEMBL18561984 0.74 F2RL3 (0.45) RXFP1YTHDC1L3MBTL1
SCHEMBL23531728 0.74 LMNA (0.45) KDM4EALDH1A1GAATSHRKMT2A
SCHEMBL10746127 0.73 TSHR (0.50) KDM4EALDH1A1GLAGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260047334-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-02-12 US disclosed
US-12331056-B2 SHP2 phosphatase inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2025-06-17 US disclosed
US-20250084090-A1 SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY Sumitomo Pharma Co., Ltd. (JP) 2025-03-13 US disclosed
EP-4506035-A2 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2025-02-12 EP disclosed
US-12180213-B2 Substituted pyrazoles showing serotonin 5-HT receptor activity SUMITOMO PHARMA CO. LTD. (JP) 2024-12-31 US disclosed
US-12084447-B2 SHP2 phosphatase inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2024-09-10 US disclosed
EP-3768668-B1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2024-08-28 EP disclosed
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2024-07-18 US disclosed
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2024-07-18 US disclosed
CN-117946098-A Pyrimidine PLK1 inhibitor and preparation method and application thereof 上海深势唯思科技有限责任公司 2024-04-30 CN disclosed
US-20040204428-A1 Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2004-10-14 US disclosed
WO-2003011864-A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2a RECEPTOR AND THEIR USE AS MEDICAMENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2003-02-13 WO disclosed
US-6030984-A 7-(4-PHENOXYPHENYL)-6-OXOQUINOLIZINES AND DERIVATIVES OF TRICYCLIC RING ANALOGUES, PARTICULARLY 7-OXOTHIENO-(2,3-A)QUINOLIZINE; INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY HOFFMANN-LA ROCHE INC. (US) 2000-02-29 US disclosed
US-5869500-A INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY HOFFMANN-LA ROCHE INC. (US) 1999-02-09 US disclosed
WO-1998025930-A2 USE OF BI- AND TRICYCLIC PYRIDONE DERIVATIVES AGAINST ALZHEIMER'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 1998-06-18 WO disclosed
US-5723468-A COGNITION ACTIVATORS FOR MEMOY LOSS AMERICAN HOME PRODUCTS CORPORATION (US) 1998-03-03 US disclosed
US-5571819-A Imidazopyridines as muscarinic agents WYETH 1996-11-05 US disclosed
US-4654350-A Gaba-agonistic imidazo(4,5-c)pyridines useful as pharmaceuticals MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1987-03-31 US disclosed
EP-0082369-B1 IMIDAZO (4,5-C) PYRIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION MERCK PATENT GmbH (DE) 1986-04-09 EP disclosed
EP-0082369-A1 Imidazo (4,5-c) pyridines, pharmaceutical compositions containing them and process for their preparation MERCK PATENT GmbH (DE) 1983-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084090-A1 SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY HTR1A, HTR5A, TPH1 KDM4E 2860/4885ALDH1A1 973/4885GLA 1306/4885
US-12180213-B2 Substituted pyrazoles showing serotonin 5-HT receptor activity HTR5A, HTR1A, TPH1 KDM4E 3105/4885ALDH1A1 753/4885GLA 3411/4885
US-20260047334-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, LDLR, OXER1 KDM4E 3832/4885ALDH1A1 1883/4885GLA 1677/4885
US-20040204428-A1 Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments ADORA2A, ADORA1, ADORA3 KDM4E 4617/4885ALDH1A1 472/4885GLA 2961/4885
US-12084447-B2 SHP2 phosphatase inhibitors and methods of use thereof PTPRCAP, PTPN22, PTPN1 KDM4E 756/4885ALDH1A1 3280/4885GLA 2925/4885
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF NRAS, BRAF, KRAS KDM4E 2695/4885ALDH1A1 1786/4885GLA 3156/4885
US-12331056-B2 SHP2 phosphatase inhibitors and methods of use thereof PTPRCAP, PTPN22, PTPN1 KDM4E 756/4885ALDH1A1 3280/4885GLA 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.